According to a new report by Expert Market Research, the South Korea Contract Development and Manufacturing Organization (CDMO) Market is experiencing robust expansion, reaching a value of USD 6.11 USD Billion in 2025 and projected to attain USD 10.14 USD Billion by 2035, growing at a CAGR of 5.2% during 2026–2035. Expert Market Research highlights that increasing biopharmaceutical outsourcing and advanced biologics manufacturing capabilities are strengthening South Korea’s position in global supply chains.

This growth is further supported by strategic infrastructure expansion and innovation-led clusters, as outlined in the . Expert Market Research emphasizes that strong government support, coupled with rising demand for biologics, is transforming the country into a major CDMO hub in Asia.

The market is driven by increasing demand for cost-efficient drug development, rising outsourcing from global pharmaceutical companies, and rapid adoption of advanced manufacturing technologies. Expert Market Research identifies that collaborations between domestic and international players are accelerating capacity expansion, particularly in biologics and cell and gene therapy segments. Additionally, favorable regulatory frameworks are enhancing export competitiveness.

Explore the Report – Free Sample with Detailed TOC Available

Overall, the market outlook remains highly positive, with sustained investments in R&D infrastructure and continuous expansion of production capabilities. Expert Market Research expects South Korea to strengthen its global leadership in high-value pharmaceutical manufacturing over the forecast period.

 

Market Overview

The South Korea CDMO market plays a pivotal role in supporting pharmaceutical innovation, large-scale biologics production, and global supply chain integration. According to Expert Market Research, the market is evolving rapidly due to increased outsourcing by global pharmaceutical and biotechnology firms. The country’s advanced manufacturing infrastructure and skilled workforce further enhance its competitiveness in high-value drug production and development services.

Expert Market Research also notes that South Korea is increasingly becoming a preferred destination for contract manufacturing due to its regulatory efficiency, strong intellectual property framework, and strategic investments in biopharma clusters such as Songdo.

Market Size & Forecast: Expert Market Research Projections

As per Expert Market Research, the South Korea CDMO market was valued at USD 6.11 USD Billion in 2025, and it is expected to grow steadily at a CAGR of 5.2% between 2026 and 2035. By the end of the forecast period, the market is projected to reach USD 10.14 USD Billion. The consistent growth reflects increasing demand for outsourced pharmaceutical development and manufacturing services.

Macroeconomic & Industry Linkage Analysis

The South Korean economy benefits significantly from its strong pharmaceutical and biotechnology sector, which contributes to export growth and industrial diversification. Expert Market Research highlights that government-backed initiatives are aligning healthcare innovation with economic development strategies.

Furthermore, global supply chain shifts and rising demand for biologics are encouraging multinational companies to expand partnerships with South Korean CDMO providers. This integration is enhancing production efficiency and strengthening the country’s global market positioning.

Key Growth Drivers

  • Rising Biologics Demand: Increasing global demand for complex biologics is driving outsourcing to advanced CDMO facilities in South Korea.
  • Government Support: Strategic investments and policies are strengthening pharmaceutical manufacturing infrastructure.
  • Technological Advancements: Adoption of automation and advanced bioprocessing technologies is improving efficiency.
  • Global Outsourcing Trends: Pharmaceutical companies are increasingly outsourcing development and manufacturing activities.
  • Expansion of CDMO Capacity: Major players are scaling production facilities to meet global demand.

Market Trends

Expert Market Research identifies a strong trend toward biologics and cell & gene therapy manufacturing, which is reshaping the competitive landscape of the CDMO industry. Companies are investing in high-tech facilities to support next-generation therapies.

Another key trend is the rise of cross-border collaborations, with South Korean firms partnering with global pharmaceutical leaders to enhance innovation and production scalability.

Market Challenges & Risk Factors

Despite strong growth, the market faces challenges such as high capital investment requirements and stringent regulatory compliance standards. Expert Market Research notes that maintaining quality consistency in large-scale biologics manufacturing remains a key operational challenge.

Additionally, global competition from established CDMO hubs poses pressure on pricing and capacity utilization, requiring continuous innovation and efficiency improvements.

Market Opportunities & White Space Areas

The expansion of advanced therapy medicinal products (ATMPs) presents significant opportunities for CDMO providers in South Korea. Expert Market Research highlights increasing investment in cell and gene therapy as a major growth avenue.

Furthermore, untapped demand in emerging therapeutic areas and expansion into global markets provide strong long-term growth potential for local CDMO companies.

Value Chain & Supply Chain Analysis

The CDMO value chain includes research and development, clinical trial manufacturing, commercial production, packaging, and distribution. Expert Market Research emphasizes that South Korea’s integrated supply chain infrastructure ensures efficiency across all stages of pharmaceutical development and production.

Market Segmentation Analysis

Breakup by Service Type

  • Contract Manufacturing Organization
  • Contract Research Organization

Breakup by Therapeutic Area

  • Oncological Diseases
  • Metabolic Disorders
  • Neurological Disorders
  • Respiratory Diseases
  • Cardiovascular Diseases
  • Infectious Diseases
  • Others

Breakup by End User

  • Pharmaceutical and Biopharmaceutical Companies
  • Medical Devices Companies
  • Others

Competitive Landscape

The South Korea CDMO market is highly competitive, with global and regional players investing in capacity expansion and technological advancement. Key companies include Vetter Pharma-Fertigung GmbH & Co. KG, Recipharm AB, Boehringer Ingelheim, Patheon Pharma Services (Thermo Fisher Scientific Inc.), Pfizer Inc., Samsung Biologics Co., Ltd., Lonza Group, CELLTRION INC., WuXi AppTec, FUJIFILM Diosynth Biotechnologies, Nipro Pharma Corporation, B. Braun SE, and WuXi Biologics. Expert Market Research highlights that strategic collaborations and facility expansions are central to maintaining competitive advantage.

Frequently Asked Questions (FAQs)

1. What is the current size of the South Korea Contract Development and Manufacturing Organization (CDMO) Market?
USD 6.11 USD Billion in 2025 as per Expert Market Research.

2. What is the projected CAGR of the South Korea Contract Development and Manufacturing Organization (CDMO) Market?
The market is expected to grow at a CAGR of 5.2% during 2026–2035.

3. Which region dominates the South Korea Contract Development and Manufacturing Organization (CDMO) Market?
South Korea dominates due to strong biopharma infrastructure and government support as noted by Expert Market Research.

4. Who are the key players in the South Korea Contract Development and Manufacturing Organization (CDMO) Market?
Samsung Biologics, Lonza Group, WuXi AppTec, Pfizer Inc., CELLTRION INC., and others.

5. What are the major growth drivers of the South Korea Contract Development and Manufacturing Organization (CDMO) Market?
Biologics demand, outsourcing trends, and government investment supported by Expert Market Research analysis.

6. What are the key segments of the South Korea Contract Development and Manufacturing Organization (CDMO) Market?
Service type, therapeutic area, and end user segments.

7. What challenges does the South Korea Contract Development and Manufacturing Organization (CDMO) Market face?
High capital costs, regulatory complexity, and global competition.

8. What is the forecast value of the South Korea Contract Development and Manufacturing Organization (CDMO) Market by 2035?
USD 10.14 USD Billion as per Expert Market Research.

"

About Us:

Expert Market Research is a global market intelligence and consulting platform by Claight delivering data-driven insights across commodities, chemicals, energy, and industrial markets. We design our research to support businesses, analysts, investors, and procurement teams in understanding price trends, supply-demand dynamics, competitive landscapes, gaining competitive intelligence, benchmarking best practices, and developing long-term market outlooks.

Our robust research methodologies, combined with validated primary and secondary data, ensure accuracy, consistency, and relevance. Our analysis is widely used not only for strategic planning, market-entry assessments, and sourcing decisions, but also for investment evaluation across international markets. Our strong emphasis on transparency, factual reporting, and regular data updates to reflect real-time market conditions always keeps you ahead of the curve.

Media Contact:

Company Name: Claight Corporation
Email: sales@expertmarketresearch.com
Toll Free Number: +1-415-325-5166 | +44-702-402-5790
Address: C-130 Sector 2 Noida, Uttar Pradesh 201301
Website: https://www.expertmarketresearch.com